ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Renal"

  • Abstract Number: 0514 • ACR Convergence 2022

    Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen

    Christine Wang1, Rebecca Sadun2, Wenru Zhou3, Kristen Miller3, Claire Palmer3, Stacy P Ardoin4, Christine Bacha5, Emily Hause6, Joyce Hui-Yuen7, Nicole Ling8, Maria Pereira9, Meredith Riebschleger10, Kelly Rouster-Stevens11, Aliese Sarkissian12, Julia Shalen13, William Soulsby14, Marinka Twilt15, Eveline Wu16, Laura Lewandowski17, Scott Wenderfer18 and Jennifer Cooper19, 1Children's Hospital of Colorado/University of Colorado, Denver, CO, 2Duke University, Durham, NC, 3University of Colorado School of Medicine, Aurora, CO, 4Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 5Nationwide Children's Hospital, Columbus, OH, 6University of Minnesota, Minneapolis, MN, 7Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, 8UCSF, San Francisco, CA, 9Baylor College of Medicine, Houston, TX, 10University of Michigan, Ann Arbor, MI, 11Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA, 12University of North Carolina at Chapel Hill, Chapel Hill, NC, 13Johns Hopkins University, Baltimore, MD, 14University of California, San Francisco, San Francisco, CA, 15Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 16University of North Carolina, Chapel Hill, NC, 17NIAMS, NIH, Bethesda, MD, 18British Columbia Children's Hospital, Vancouver, BC, Canada, 19Children's Hospital of Colorado/University of Colorado, Aurora, CO

    Background/Purpose: There have been no published studies comparing renal outcomes of youth with proliferative lupus nephritis (LN) treated with the lower-dose EuroLupus (EL) cyclophosphamide (CYC)…
  • Abstract Number: 1829 • ACR Convergence 2022

    Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study

    Lindsay Helget1, Anne Davis-Karim2, James O'Dell1, Ted Mikuls3, Jeff Newcomb1, Maria Androsenko4, Mary Brophy4, Bryant England1, Ryan Ferguson4, Michael Pillinger5, Tuhina Neogi6, Hongsheng Wu4 and Paul Palevsky7, 1University of Nebraska Medical Center, Omaha, NE, 2VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, 5NYU Grossman School of Medicine, New York, NY, 6Boston University School of Medicine, Boston, MA, 7University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh

    Background/Purpose: Urate lowering therapy (ULT) is a cornerstone in the treatment of gout, which afflicts over 2 million individuals with chronic kidney disease (CKD) in…
  • Abstract Number: 0655 • ACR Convergence 2022

    Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents

    Alessandra Ida Celia1, Jeffery Hodgin2, Avi Rosenberg3, Laurence S Magder4, Jill Buyon5, Betty Diamond6, Judith James7, William Apruzzese8, Paride Fenaroli9, Derek Fine1, Jose Monroy-Trujillo1, Mohamed G. Atta1, Peter izmirly10, Michael Belmont5, Anne Davidson6, Daniel W. Goldman11, the Accelerating Medicines Partnership (AMP) RA/SLE12, Michelle Petri11 and Andrea Fava1, 1Johns Hopkins University, Baltimore, MD, 2University of Michigan, Ann Arbor, MI, 3Johns Hopkins University, Ballwin, MO, 4University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 5NYU Grossman School of Medicine, New York, NY, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Brigham and Women's Hospital, Boston, MA, 9Università degli Studi di Parma, Parma, Emilia-Romagna, Italy, 10NYU Long Island School of Medicine, New York, NY, 11Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 12Multiple Insitutions

    Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…
  • Abstract Number: 0929 • ACR Convergence 2022

    Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases

    Cara Kumar1, Kristine Herrmann1 and Martin Aringer2, 1Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 2University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany

    Background/Purpose: While mostly remarkably safe, low dose methotrexate (MTX) occasionally causes life-threatening events. We analyzed all patients with rheumatic diseases and severe MTX toxicity between…
  • Abstract Number: 1055 • ACR Convergence 2022

    Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study

    Alex Luta1, Saloni Godbole1 and Virginia Steen2, 1Medstar Georgetown University Hospital, Washington, DC, 2Georgetown University School of Medicine, Washington, DC

    Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe and life-threatening complication of Systemic Sclerosis (SSc). Given the rare nature of SSc, it is challenging to…
  • Abstract Number: 1069 • ACR Convergence 2022

    Renal Involvement Other Than Renal Crisis in Systemic Sclerosis: A Retrospective Monocentric Cohort Study

    Gaelle Becel1, Bertrand Dunogue1, Benjamin Chaigne1, Benjamin Thoreau2, Alexis Regent1, Alexandre Karras3, Benjamin Terrier1 and Luc Mouthon1, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, 3HEGP, Paris, France

    Background/Purpose: Scleroderma renal crisis has extensively been described over the past decades because of its severity. The use of angiotensin-converting enzyme inhibitors has clearly improved…
  • Abstract Number: 1073 • ACR Convergence 2022

    Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan

    Soko Kawashima1, Mitsumasa Kishimoto2, Yoshinori Komagata3 and Shinya kaname4, 1Kyorin University, Mitaka Tokyo, Japan, 2Kyorin University School of Medicine, Yokohama, Japan, 3Kyorin University School of Medicine, Tokyo, Japan, 4Kyorin University, Tokyo, Japan

    Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
  • Abstract Number: 1083 • ACR Convergence 2022

    Treatment of ANCA-associated Vasculitis with Extreme Impairment of Renal Function: A Case-Control Study Comparing an Intensive B Cell Depletion Regimen with the Standard of Care Using Oral Cyclophosphamide

    Dario Roccatello1, Savino Sciascia2, Stefano Murgia1, Giacomo Quattrocchio1, Michela Ferro1, Emanuele De Simone1, Carla Naretto1, Antonella Barreca1, Daniela Rossi1, Vittorio Modena1 and Roberta Fenoglio1, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy

    Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitis associated with antineutrophil cytoplasm antibodies (AAV) in…
  • Abstract Number: 1089 • ACR Convergence 2022

    Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

    Yeo jin lee1, Soo Min Ahn2, Ji Seon Oh3, Yong Gil Kim2, Chang Keun Lee2, Bin Yoo2 and Seokchan Hong2, 1Asan medical center, Seoul, Republic of Korea, 2Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 3Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea

    Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease that can involve various organs systematically. Kidney involvement, one of the major manifestations of AAV,…
  • Abstract Number: 1360 • ACR Convergence 2022

    Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide

    Christine Wang1, Rebecca Sadun2, Wenru Zhou3, Kristen Miller3, Claire Palmer3, Stacy P Ardoin4, Christine Bacha5, Emily Hause6, Joyce Hui-Yuen7, Nicole Ling8, Maria Pereira9, Meredith Riebschleger10, Kelly Rouster-Stevens11, Aliese Sarkissian12, Julia Shalen13, William Soulsby14, Marinka Twilt15, Eveline Wu16, Laura Lewandowski17, Scott Wenderfer18 and Jennifer Cooper19, 1Children's Hospital of Colorado/University of Colorado, Denver, CO, 2Duke University, Durham, NC, 3University of Colorado School of Medicine, Aurora, CO, 4Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 5Nationwide Children's Hospital, Columbus, OH, 6University of Minnesota, Minneapolis, MN, 7Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, 8UCSF, San Francisco, CA, 9Baylor College of Medicine, Houston, TX, 10University of Michigan, Ann Arbor, MI, 11Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 12University of North Carolina at Chapel Hill, Chapel Hill, NC, 13Johns Hopkins University, Baltimore, MD, 14University of California, San Francisco, San Francisco, CA, 15Alberta Children's Hospital, Calgary, AB, Canada, 16University of North Carolina, Chapel Hill, NC, 17NIAMS, NIH, Bethesda, MD, 18British Columbia Children's Hospital, Vancouver, BC, Canada, 19University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
  • Abstract Number: L14 • ACR Convergence 2021

    Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis

    David Jayne1, Peter Merkel2, Annette Bruchfeld3, Duvuru Geetha4, Alexandre Karras5, John Niles6 and Pirow Bekker7, 1University of Cambridge, Cambridge, United Kingdom, 2University of Pennsylvania, Philadelphia, PA, 3Linköping University, Linköping, Sweden, 4Johns Hopkins University, Baltimore, MD, 5Hopital Europeen Georges Pompidou, Paris, France, 6Massachusetts General Hospital, Boston, MA, 7ChemoCentryx, Inc., San Carlos, CA

    Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood vessels; renal disease is…
  • Abstract Number: 1757 • ACR Convergence 2021

    Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series

    Matthew Snyder1, Angel Chen1, Sonali Narain2 and Galina Marder2, 1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell at Lenox Hill Hospital Program, New York, NY, 2Northwell Health, Great Neck, NY

    Background/Purpose: Belimumab is FDA approved for treatment of SLE and Lupus Nephritis. Patients with an eGFR < 30 ml/min/1.73m2 were excluded from clinical trials, thus…
  • Abstract Number: 1937 • ACR Convergence 2021

    IL-16 Is Linked to Lupus Nephritis Activity

    Andrea Fava1, Deepak Rao2, Chandra Mohan3, Ting Zhang3, Avi Rosenberg1, Paride Fenaroli4, H. Michael Belmont5, Peter Izmirly6, Robert Clancy7, Jose Monroy-Trujillo1, Derek Fine1, Arnon Arazi8, Celine Berthier9, Anne Davidson10, Judith James11, Betty Diamond12, Nir Hacohen13, David Wofsy14, Soumya Raychaudhuri2, Accelerating Medicines Partership (AMP) RA/SLE Network15, Jill Buyon5, Michelle Petri16 and The Accelerating Medicines Partnership in RA/SLE17, 1Johns Hopkins University, Baltimore, MD, 2Brigham and Women's Hospital, Boston, MA, 3University of Houston, Houston, TX, 4Universita` degli Studi di Parma, Parma, Italy, 5NYU School of Medicine, New York, NY, 6New York University School of Medicine, New York, NY, 7NYU Grossman School of Medicine, New York, NY, 8Feinstein Institutes for Medical Research, Melrose, MA, 9University of Michigan, Ann Arbor, MI, 10Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 11Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Northwell Health, Manhasset, NY, 13Broad Institute, Cambridge, MA, 14University of California San Francisco, San Francisco, CA, 15Brigham and Women's Hospital, Everett, MA, 16Johns Hopkins University School of Medicine, Baltimore, MD, 17Multiple Institutions, Multiple

    Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…
  • Abstract Number: 0327 • ACR Convergence 2021

    Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency

    Caoilfhionn Connolly1, Jessica Li2, Daniel Goldman3, Andrea Fava2, Laurence Magder4 and Michelle Petri3, 1Johns Hopkins, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease. Cardiovascular disease is one of the leading causes of death in patients…
  • Abstract Number: 0419 • ACR Convergence 2021

    Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study

    Gregory McDermott1, Xiaoqing Fu2, Claire Cook3, John Stone4, Yuqing Zhang5 and Zachary Wallace6, 1Brigham and Women's Hospital, Brookline, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 5Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, 6Massachusetts General Hospital, Newton, MA

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is associated with increased risk of end-stage renal disease (ESRD) and death. In most cases, circulating ANCA targeting…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology